Precision BioSciences Q4 net income $20.1M, PBGENE-HBV shows antiviral activity, cash runway through 2028

PRECISION BIOSCIENCES INC

Q4 net income $20.1M ($1.05 diluted EPS) vs net loss $17.8M YoY; FY net loss $45.7M ($3.56/sh).
Cash, equivalents, restricted cash $137.2M as of Dec 31, 2025; $75M Nov 2025 financing extends runway through 2028.
PBGENE-HBV Phase 1: 13 patients dosed across 5 cohorts; late-breaking data showed safety, dose-dependent antiviral activity and HBsAg declines.
PBGENE-DMD received IND clearance Feb 2026; Fast Track & Orphan Drug designations; initial data from multiple patients expected year-end 2026.
Milestone payments: $8M from Imugene (Oct 2025) and $7.5M from TG Therapeutics (Mar 2026).

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

PRECISION BIOSCIENCES INC reported financial results for the fourth quarter and fiscal year ended December 31, 2025.

Period: the fourth quarter and fiscal year ended December 31, 2025
Result: reported results

Exact text from the filing

On March 12, 2026, Precision BioSciences, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and year ended December 31, 2025.

View on SEC.gov

Browse all earnings releases →

PRECISION BIOSCIENCES INC filing history →

Source: SEC EDGAR

accession 0001628280-26-017018

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.